|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Recent trends in liver transplantation for alcoholic liver disease in the United States显示文摘AIM To examine temporal changes in the indications for liver transplantation(LT) and characteristics of patients transplanted for alcoholic liver disease(ALD).METHODS We performed a retrospective cohort analysis of trends in the indication for LT using the United Network for Organ Sharing(UNOS) database between 2002 and 2015. Patients were grouped by etiology of the liver disease and characteristics were compared using χ~2 and t-tests. Time series analysis was used identifying any year with a significant change in the number of transplants per year for ALD, and before and after eras were modeled using a general linear model. Subgroup analysis of recipients with ALD was performed by age group, gender, UNOS region and etiology(alcoholic cirrhosis, alcoholic hepatitis and hepatitis C-alcoholic cirrhosis dual listing).RESULTS Of 74216 liver transplant recipients, ALD(n = 9400, 12.7%) was the third leading indication for transplant after hepatitis C and hepatocellular carcinoma. Transplants for ALD, increased from 12.8%(553) in 2002 to 16.5%(1020) in 2015. Time series analysis indicated a significant increase in the number of transplants per year for ALD in 2013(P = 0.03). There were a stable number of transplants per year between 2002 and 2012(linear coefficient 3, 95%CI:-4.6, 11.2) an increase of 177 per year between 2013 and 2015(95%CI: 119, 234). This increase was significant for all age groups except those 71-83 years old, was observed for both genders, and was incompletely explained by a decrease in transplants for hepatitis C and ALD dual listing. All UNOS regions except region 9 saw an increase in the mean number of transplants per year when comparing eras, and this increase was significant in regions 2, 3, 4, 5, 6, 8, 10 and 11.CONCLUSION There has been a dramatic increase in the number of transplants for ALD starting in 2013. | Catherine E Kling James D Perkins Robert L Carithers Dennis M Donovan Lena Sibulesky | 2017 | World Journal of Hepatology2017，9，36： | 6 |
| 2 | 利用抗高血压药相关的遗传变异发现其潜在的功效和副作用显示文摘通过研究药物靶蛋白基因的自然变异可以了解药物的功效。本研究旨在利用这种方法探索抗高血压药的潜在副作用和再利用潜力。研究者首先确定了血管紧张素转换酶抑制剂(angiotensin converting enzyme inhibitor,ACEI)、β受体阻滞剂和钙拮抗剂的合适代表基因。 | 刘青(译) 叶鹏(校) Gill D Georgakis MK Koskeridis F Jiang L Feng Q Wei WQ Theodoratou E Elliott P Denny JC Malik R Evangelou E Dehghan A Dichgans M Tzoulaki I | 2019 | 中华高血压杂志2019，0，9： | 3 |
| 3 | Epistaxis in end stage liver disease masquerading as severe upper gastrointestinal hemorrhage显示文摘AIM:To describe the prevalence,diagnosis,treatment,and outcomes of end stage liver disease(ESLD) patients with severe epistaxis thought to be severe upper gastrointestinal hemorrhage(UGIH).METHODS:This observational single center study included all consecutive patients with ESLD and epistaxis identified from consecutive subjects hospitalized with suspected UGIH and prospectively enrolled in our databases of severe UGIH between 1998 and 2011.RESULTS:A total of 1249 patients were registered for severe UGIH in the data basis,461(36.9%) were cirrhotics. Epistaxis rather than UGIH was the bleeding source in 20 patients. All patients had severe coagulopathy. Epistaxis was initially controlled in all cases. Fifteen(75%) subjects required posterior nasal packing and 2(10%) embolization in addition to correction of coagulopathy. Five(25%) patients died in the hospital,12(60%) received orthotopic liver transplantation(OLT),and 3(15%) were discharged without OLT. The mortality rate was 63% in patients without OLT.CONCLUSION:Severe epistaxis in patients with ESLD is(1) a diagnosis of exclusion that requires upper endoscopy to exclude severe UGIH;and(2) associated with a high mortality rate in patients not receiving OLT. | Marine Camus Dennis M Jensen Jason D Matthews Gordon V Ohning Thomas O Kovacs Rome Jutabha Kevin A Ghassemi Gustavo A Machicado Gareth S Dulai | 2014 | World Journal of Gastroenterology2014，20，38： | 3 |
| 4 | 地中海膳食干预研究中来自胆碱通路的血浆代谢物与心血管病风险的关系显示文摘血浆甜菜碱水平以及胆碱代谢水平与主要心血管病终点之间的联系仍不清楚。研究者评估了胆碱通路的代谢物与偶发心血管病风险以及地中海膳食干预的潜在调节效应之间的相关性。 | 黄洁 叶鹏 Guasch-Ferré M Hu FB Ruiz-Canela M Bulló M Toledo E Wang DD Corella D Gómez-Gracia E Fiol M Estruch R Lapetra J Fitó M Arós F Serra-Majem L Ros E Dennis C Liang L Clish CB Martínez-González MA Salas-Salvadó J | 2017 | 中华高血压杂志2017，25，12： | 2 |
| 5 | Precision atomic gravimeter based on Bragg diffraction显示文摘 | P A Altin M T Johnsson V Negnevitsky G R Dennis R P Anderson J E Debs S S Szigeti K S Hardman S Bennetts G D McDonald L D Turner J D Close N P Robins | 2013 | New Journal of Physics2013，，2： | 2 |
| 6 | Survival after inflammatory bowel disease-associated colorectal cancer in the Colon Cancer Family Registry显示文摘AIM: To investigate the survival of individuals with colorectal cancer (CRC) with inflammatory bowel disease (IBD-associated CRC) compared to that of individuals without IBD diagnosed with CRC. METHODS: Epidemiologic, clinical, and follow-up data were obtained from the Colon Cancer Family Registry (Colon CFR). IBD-associated cases were identified from self-report of physician diagnosis. For a subset of participants, medical records were examined to confirm self-report of IBD. Cox proportional hazards regression was applied to estimate adjusted hazard ratios (aHR) and 95%CI of mortality, comparing IBD-associated to non-IBD-associated CRC, adjusted for age at CRC diagnosis, sex, Colon CFR phase, and number of prior endoscopies. Following imputation to complete CRC stage information, adjustment for CRC stage was examined. RESULTS: A total of 7202 CRC cases, including 250 cases of IBD-associated CRC, were analyzed. Over a twelve year follow-up period following CRC diagnosis, 2013 and 74 deaths occurred among non-IBD associated CRC and IBD-associated CRC patients, respectively. The difference in survival between IBD-associated and non-IBD CRC cases was not statistically significant (aHR = 1.08; 95%CI: 0.85-1.36). However, the assumption of proportional hazards necessary for valid inference from Cox regression was not met over the entire follow-up period, and we therefore limited analyses to within five years after CRC diagnosis when the assumption of proportional hazards was met. Over this period, there was evidence of worse prognosis for IBD-associated CRC (aHR = 1.36; 95%CI: 1.05-1.76). Results were similar when adjusted for CRC stage, or restricted to IBD confirmed in medical records. CONCLUSION: These results support the hypothesis that IBD-associated CRC has a worse prognosis than non-IBD-associated CRC. | Scott V Adams Dennis J Ahnen John A Baron Peter T Campbell Steven Gallinger William M Grady Loic LeMarchand Noralane M Lindor John D Potter Polly A Newcomb | 2013 | World Journal of Gastroenterology2013，19，21： | 2 |
| 7 | Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR1 genes and pharmacokinetics ofthe calcineurin inhibitors cyclosporine and tacrolimus显示文摘 | DENNIS A HCSSELINK M D | 2003 | Clin Pharnuwol Ther2003，74，： | 1 |
| 8 | Rubber elongation by farnesyl pyrophosphate synthases involves a novel switch in enzymes tereospecificity 显示文摘 | LIGHT D R LAZARUS R A DENNIS M S | 1989 | The Journal of Biological Chemistry1989，264，18： | 1 |
| 9 | Primary vaginal melanoma Thirteen -year disease-free survival after wide local excision and review of recent literature显示文摘 | Dennis J Buchanan M D John Schlaerth M D | 1998 | Am Obstet Gynecol1998，178，3： | 1 |
| 10 | Rubber elongation factor from Hevea brasiliensis 显示文摘 | DENNIS M S LIGHT D R | 1989 | The Journal of Biological Chemistry1989，264，18： | 1 |
| 11 | Cloning and sequencing of the cDNA encoding the rubber elongation factor of Hevea brasiliensis显示文摘 | GOYVAERTS E DENNIS M LIGHT D | 1991 | Plant Physiology1991，97，1： | 1 |
| 12 | Combination therapy with trastuzuanrb (Hecreptin) and cispaltin for chemoresist intantmetastatci breast cancer; evidence for receptor-enhanced chemosensitive显示文摘 | Pegram M D Slamon D J Dennis J S | 1999 | Semin Oncol1999，26，： | 1 |
| 13 | Repeated administration of synthetic oligodoxynucleotides expressing CpG motifys provides long-term protection against bacterial infection 显示文摘 | Dennis M Klinman D M Jackie C | 1999 | Infection and Immunity1999，67，11： | 1 |
| 14 | β-amyloid degradation and Alzheimer's disease显示文摘 | Deng S W Dennis W D James S M | 2006 | Journal of Biomedicine and Biotechnology2006，2006，58： | 1 |
| 15 | Rubber elongation factors from Heyea brasiliensis显示文摘 | Dennis M Light D | 1989 | The Journal of Biological Chemistry1989，264，18： | 1 |
| 16 | Genome size is negatively correlated with altitude in natural populations of Dactylis glomerata显示文摘 | Reeves Dennis F M Stuart D | 1998 | Annals of Botany1998，82，： | 1 |
| 17 | New nitrate- based treatments control hydrogen sulfide in reservoirs 显示文摘 | HITZMAN D O DENNIS M | 2004 | World Oil2004，225，11： | 1 |
| 18 | Precision and bias of target controlled propofol infusion for sedation显示文摘 | Frolich M A Dennis D M Shuster J A | 2005 | Br J Anaesth2005，94，4： | 1 |
| 19 | Comparison between microwave and conventional sintering of WC/Co composites 显示文摘 | BREVAL E CHENG J P AGRAWAL D K GIGL P DENNIS M ROY R PAPWORTH A J | 2005 | Materials Science and Engineering A2005，391，12： | 1 |
| 20 | Why Use Clinical Pathways Rather than Prac- tice Guide Lines?显示文摘 | Dennis E Weiland M D | 1997 | Am J Surg1997，，174： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员